Want to invest in AI, but can't decide on which AI stocks to buy? We get it. That's why so many people are looking for an AI ETF to invest in instead. But, which AI ETF is the best? We can help with that. We start with a list of 40 AI ETFs from VettaFi and remove those that are simply broad sector ETFs. We also weed out any of the ETFs that have too little assets under management, or a lack of conviction measured by a lack of concentration. In the end, we found 5 AI ETFs we like best. Watch...

Cathie Wood of ARK Invest is predicting trillions of dollars in profits for these five technology niches: Artificial Intelligence, Blockchain, Multiomics, Energy Storage, and Robotics. Today we'll analyze these technologies as well as comment on the stocks Cathie has picked to represent these technologies. We need to preface this information with the fact that ARK Invest primarily offers actively managed funds, and only 5% of active managers can actually outperform a benchmark. Cathie has a...

AbCellera stock was a pandemic darling, with their first day of trading seeing a valuation of nearly $13 billion. The AI drug discovery stock - which we happen to like - has now tumbled over 90%, leaving investors wondering whether it's time to buy. We see a lot of appeal in a platform that can reduce the time it takes to bring drugs to market, especially one that was tested and proven in the times of the 'Rona. But why do they now only have six noteworthy molecules in the clinic? And why...

Reddit stock began trading last Thursday under the ticker RDDT. Some are calling $RDDT an AI stock since the company plans to begin licensing its data for the use of large language model training. Their popular "upvote" mechanic acts as a community notes function to help validate data. This is certainly interesting, and while we don't find Reddit to be terribly overvalued based on our simple valuation ratio, we have some concerns around how the platform plans to monetize its users. With 50%...

Stop losses sound ideal. Buy a stock and limit your downside to whatever amount you're comfortable with - great! Not so much. Stop loss orders should really be called "realize loss" orders as they lock in your losses leaving you to guess when and how to get back in. And if you don't want to get back in, then why did you even buy the stock to begin with? Stop loss orders simply have no place in the portfolio of a long-term investor, someone who wants to build wealth over the next few decades...

Buying TSLA stock? You'll want to watch this first. We construct an actual price target for Tesla - not just the usual "going to 10x, get in now!" type of rubbish that you see on Twitter. We look at Tesla's historical valuation compared to its current market cap with today's revenues and shares outstanding to determine where we'd be buyers of TSLA shares. We also talk about some of the risks surrounding Tesla stock, like the great almighty Elon Musk himself. It's a double-edged sword as...

Generative AI is all anyone can talk about these days, so we'd expect it to be a massive investment opportunity. Our video looks at who stands to benefit most from generative artificial intelligence, and what some of the use cases might look like. Some of the main beneficiaries of the technology include banking support, high tech coding, and R&D in the life science industry. Interestingly, most of the opportunity is already being realized today through "legacy AI" offerings. Is the...

Invitae went bankrupt, and we lost everything. Well, not *everything*. But, we learned some valuable lessons we'll apply going forward. Today's video touches on our tech stock investing methodology, why we purchased NVTA stock in the first place, how we limited our losses, and what we'll do going forward to avoid another situation like this one. Why are we talking about our biggest loser? Well, honesty and integrity are important to us here at Nanalyze. We can't bring up our massive NVIDIA...

Blockchain is one of the many disruptive technologies we cover. It's also the only one with an annual "Crime Report". As of March 2024, the biggest application of blockchain technology, Bitcoin, was hitting new highs. With the rise of bitcoin price comes inevitable hype for "blockchain stocks". MicroStrategy MSTR is one such stock. Though the company's actual business is an enterprise analytics software platform that hasn't managed to grow, MicroStrategy is considered a blockchain stock due...

Recursion stock has seen quite a bit of hype after NVIDIA announced an ownership stake in the AI drug discovery firm last summer. We happen to like RXRX stock, so we decided to take a look under the hood and see if the company is living up to the hype. What we uncovered is a very capital-intensive business model that has so far been funded by injections from pharma partners like Roche, or by dilution of shareholders in the form of stock offerings. With their current cash balance and burn...

AI stocks are all anyone can talk about. The very definition of the term "AI stock" has shifted so much that we're apparently calling Meta and Cloudflare "AI stocks" now. Our mission today is to look at the artificial intelligence hype and determine whether we're in the midst of another dot-com-type bubble, or whether it's actually different this time. To do that, we need to separate the financials from the hype. Remember, we invest in companies, not stocks. Companies like Soundhound.ai...

SCHD ETF has attracted a lot of attention from retail investors looking to get exposure to a diversified basket of dividend growth stocks with a low expense ratio. We've analyzed the ETF numerous times and found it to be the most attractive dividend growth ETF out there. But, can our own stock picks beat SCHD? They sure can. Recently, a couple of our BSD analysts put together a very detailed research paper comparing the performance of our proprietary Quantigence dividend growth strategy...

The three-stock portfolio has been a hot topic on our premium Discord server lately, understandably so. This passive portfolio was the work of John Bogle, founder and ex-CEO of Vanguard, known for their low-cost index funds. Bogle's advice is so sound that it's resonated with a community of 120,000 people who call themselves "Bogleheads". The Bogleheads are a group of like-minded individuals with a mission to make sure investors get their fair share of the market returns. They emphasize...

NVIDIA stock's massive success in the GPU market is thanks to huge generative AI demand. In fact, generative AI currently sits at the top of Gartner's hype cycle. So, what happens when that demand dries up? Will NVDA stock crash? The trough of disillusionment. This is where interest wanes as experiments and implementations fail to deliver. At a certain point, the market is likely to realize that it's vastly overestimated the potential of generative AI... according to Gartner. Do you...

Ginkgo Bioworks $DNA released their 2023 results, and it's not pretty. Downstream revenues are drying up, and milestone pool opportunities aren't providing as many growth opportunities as investors had hoped. Cell engineering revenues disappointed with only $144 million in 2023 versus the expected $175 million - flat revenue growth year-over-year. Will Ginkgo be able to turn this ship around? Or is the synthetic biology company just another wonderful story? Stay informed with our free...

Fastly stock (FSLY) was recommended to us by one of our loyal patrons on our Discord server. Our community voted for us to cover the stock, so here we are. Fastly recently reported slowing revenue growth, leading to a -30% decline in share price, and then some. This stock has become very popular, leaving investors wondering whether there is any value to be had here. Today we'll analyze Fastly and compare it against the elephant in the room, Cloudflare. Would we be interested in buying FSLY...

AI stocks are all anyone can talk about these days, so it's no surprise to see a hot new artificial intelligence stock hitting the market via an IPO. Astera Labs is a data center connectivity startup seeking $100M in an IPO that could launch as soon as March 2024. The proposed IPO valuation will be around $4 billion. Astera supplies networking chips to cloud operators, putting it right in the heart of a few exciting disruptive themes like cloud computing and AI. Sounds like a lot of hype...

Rivian stock was down 25% after their recent earnings report. Is RIVN a "buy the dip" opportunity, or a falling knife? We'll look at Rivian's earnings and see what progress they're making on improving their gross margins which are currently negative. We'll also talk about their cash balance and survivability. While Rivian isn't likely to go bankrupt tomorrow, they're also not thriving. Turns out electric trucks are pretty damn expensive to produce, and it's hard to convince people to shell...

LUNR stock price has soared. Again. Intuitive Machines is planning their first private moon landing today, sending shares to the moon. We first covered this space SPAC one year ago when their shares were seeing a level of hype that was detached from reality. We're beginning to see that hype creeping back, so it's time to look at what's going on with LUNR stock and see if our thesis has changed with Intuitive Machines. Do we think a successful landing of their Odysseus machine will generate...

Materials stocks don't get a lot of love from dividend investors because they're often overlooked. While making up only 2.5% of the S&P 500, the Materials sector contains lots of great dividend champions In this video, we discuss five materials stocks that also happen to be dividend aristocrats: Linde LIN, Air Products & Chemicals APD, Sherwin Williams SHW, PPG International PPG, and RPM International RPM. We own two of these five stocks, but you'll have to watch the video to find out...

Brainchip stock is full of promise, but lacks execution. The company has achieved roughly $10 million in total revenue over the past decade. That's how much revenue we expect a company to make in a single year before we'd even begin to take a look at it. On top of that, Brainchip exhibits all the red flags we look out for, including press release overload and extensive "customers" that don't account for any meaningful revenue. So, why did we make this video? We're not shorting Brainchip...

NVIDIA stock has been rallying lately due to extraordinary demand for their GPUs for AI applications such as ChatGPT. With the stock up over 200% in the past year versus a 40% return of the Nasdaq, investors may be left wondering whether NVDA stock is overvalued. Today we'll analyze NVIDIA stock using our simple valuation ratio as well as the traditional P/E ratio, and we'll do it step-by-step so you can do the same. Turns out you can make a case for NVIDIA stock not being overvalued using...

Everyone is talking about JEPI, few are talking about holding JP Morgan's Equity Premium Income ETF is a bad idea. That's because 80% of the "income" being generated by this active investment strategy comes from selling covered calls. They're not covered calls, they're equity linked notes ELNs, people will say. Correct. JEPI's fund managers don't log into Robinhood and sell covered calls all day. An ETF with $32 billion in assets needs to do things differently which is why they use ELNs to...

Wolfspeed stock keeps hitting new lows as investors ask an important question. Is WOLF stock a good buy or a trap? We start by looking at the broader silicon carbide SiC thesis with a look at how China may become a major player with lots of SiC wafer production coming online. Then, we touch on the Tesla announcement of plans to cut back on silicon carbide usage in their electric vehicles, and how that may not matter all that much provided the costs of silicon carbide can fall enough to spur...

Gene editing investors may soon have one more stock to choose from. A gene-editing company called Metagenomi $MGX uses AI to discover novel CRISPR gene editing methods from nature and they're planning to have an IPO. We start by looking at all the current players according to the IPO S-1 filing, then describe what the ideal gene editing business model looks like. Then, we describe how MGX plans to compete against CRISPR CAS9 competitors like CRISPR Therapeutics and Intellia Therapeutics....